David Nierengarten
Stock Analyst at Wedbush
(4.53)
# 322
Out of 5,182 analysts
233
Total ratings
57.71%
Success rate
19.6%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $4.27 | +157.61% | 7 | Apr 20, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $53 → $58 | $43.61 | +33.00% | 7 | Apr 16, 2026 | |
| NVCR NovoCure | Reiterates: Neutral | $18 | $12.48 | +44.23% | 10 | Apr 16, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $4.56 | +141.23% | 15 | Apr 16, 2026 | |
| FENC Fennec Pharmaceuticals | Reiterates: Outperform | $13 | $6.83 | +90.34% | 4 | Apr 16, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $65 → $80 | $71.90 | +11.27% | 2 | Apr 14, 2026 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $10.40 | +111.54% | 5 | Apr 13, 2026 | |
| NUVL Nuvalent | Reiterates: Outperform | $125 | $104.04 | +20.15% | 7 | Apr 8, 2026 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $20 → $17 | $10.19 | +66.83% | 11 | Apr 1, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $56 → $58 | $46.29 | +25.30% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $22.48 | +33.48% | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $36.61 | +50.25% | 5 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,000 | $783.74 | +27.59% | 25 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $8 | $7.72 | +3.63% | 2 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $1.31 | +281.68% | 5 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $95 | $86.49 | +9.84% | 4 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $65 | $29.17 | +122.87% | 4 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $110 | $111.90 | -1.70% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $88 | $68.85 | +27.81% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $23.49 | +31.97% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $8.79 | +184.41% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $13.04 | -46.32% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.31 | +434.35% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $13.10 | +98.47% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $14.12 | -43.34% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $33.59 | -40.46% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $66.59 | -39.93% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $76.39 | -47.64% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $10.75 | +67.44% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.67 | +226.98% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $1.14 | +43,759.65% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $8.66 | +592.84% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $23.99 | +212.63% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.47 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.76 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.79 | - | 3 | Nov 20, 2017 |
Perspective Therapeutics
Apr 20, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.27
Upside: +157.61%
Kiniksa Pharmaceuticals International,
Apr 16, 2026
Maintains: Outperform
Price Target: $53 → $58
Current: $43.61
Upside: +33.00%
NovoCure
Apr 16, 2026
Reiterates: Neutral
Price Target: $18
Current: $12.48
Upside: +44.23%
Nuvation Bio
Apr 16, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.56
Upside: +141.23%
Fennec Pharmaceuticals
Apr 16, 2026
Reiterates: Outperform
Price Target: $13
Current: $6.83
Upside: +90.34%
Spyre Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $65 → $80
Current: $71.90
Upside: +11.27%
Telix Pharmaceuticals
Apr 13, 2026
Reiterates: Outperform
Price Target: $22
Current: $10.40
Upside: +111.54%
Nuvalent
Apr 8, 2026
Reiterates: Outperform
Price Target: $125
Current: $104.04
Upside: +20.15%
ORIC Pharmaceuticals
Apr 1, 2026
Maintains: Outperform
Price Target: $20 → $17
Current: $10.19
Upside: +66.83%
Scholar Rock Holding
Apr 1, 2026
Maintains: Outperform
Price Target: $56 → $58
Current: $46.29
Upside: +25.30%
Mar 31, 2026
Reiterates: Outperform
Price Target: $30
Current: $22.48
Upside: +33.48%
Mar 17, 2026
Reiterates: Outperform
Price Target: $55
Current: $36.61
Upside: +50.25%
Mar 9, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $783.74
Upside: +27.59%
Mar 6, 2026
Maintains: Outperform
Price Target: $4 → $8
Current: $7.72
Upside: +3.63%
Mar 5, 2026
Maintains: Outperform
Price Target: $4 → $5
Current: $1.31
Upside: +281.68%
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $86.49
Upside: +9.84%
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $29.17
Upside: +122.87%
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $111.90
Upside: -1.70%
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $68.85
Upside: +27.81%
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $23.49
Upside: +31.97%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $8.79
Upside: +184.41%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $13.04
Upside: -46.32%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.31
Upside: +434.35%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $13.10
Upside: +98.47%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $14.12
Upside: -43.34%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $33.59
Upside: -40.46%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $66.59
Upside: -39.93%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $76.39
Upside: -47.64%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $10.75
Upside: +67.44%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.67
Upside: +226.98%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $1.14
Upside: +43,759.65%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $8.66
Upside: +592.84%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $23.99
Upside: +212.63%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.47
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.76
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $10.79
Upside: -